Undervalued Industry Leader with a 5% Yield

Share with your friends










Submit

This stock lacks the revenue growth potential of some biotech peers, but it also lacks the cash burn and often binary uncertainty. It bears closer resemblance to a traditional pharma stock with biotech characteristics. Given the company’s industry leading position, solid fundamentals and attractive stock valuation, we view it as a preferable alternative to traditional drug stocks. It offers lower-risk exposure to biotech innovation as an added bonus.

Not a Member Yet?

You need a Gold Membership or higher to view the content on this page.
Start Your Gold Membership Today | Members Log In Here

Photo Credit: TheFemGeek (Flickr)

1 Comment

  • Patrick

    May 8, 2017

    Will you offer the Scottrade discount to TD Ameritrade account holders since they are owned by the same parent?

Leave A Response

* Denotes Required Field